Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant‐induced inflammatory pain

Essentials The role of platelet P2Y12 receptors in the regulation of chronic inflammatory pain is unknown. Complete Freund's Adjuvant (CFA)‐induced chronic inflammatory pain model was used in mice. Gene deficiency and antagonists of P2Y12 receptors attenuate hyperalgesia and local inflammation....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of thrombosis and haemostasis Ročník 15; číslo 6; s. 1223 - 1235
Hlavní autoři: Bekő, K., Koványi, B., Gölöncsér, F., Horváth, G., Dénes, Á., Környei, Z., Botz, B., Helyes, Z., Müller, C. E., Sperlágh, B.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Oxford Elsevier Limited 01.06.2017
Témata:
cytokines
Freund's adjuvant
Inflammation
Interleukin 1
Interleukin 6
P2Y12 purinoceptor
Pain
Pain perception
Peroxidase
platelet activation
Platelet aggregation
Platelets
Rodents
Sodium channels (voltage-gated)
Tumor necrosis factor
Tumor necrosis factor-TNF
ISSN:1538-7933, 1538-7836, 1538-7836
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Essentials The role of platelet P2Y12 receptors in the regulation of chronic inflammatory pain is unknown. Complete Freund's Adjuvant (CFA)‐induced chronic inflammatory pain model was used in mice. Gene deficiency and antagonists of P2Y12 receptors attenuate hyperalgesia and local inflammation. Platelet P2Y12 receptors contribute to these effects in the chronic phase of inflammation. Summary Background P2Y12 receptor antagonists are widely used in clinical practice to inhibit platelet aggregation. P2Y12 receptors are also known to regulate different forms of pain as well as local and systemic inflammation. However, it is not known whether platelet P2Y12 receptors contribute to these effects. Objectives To explore the contribution of platelet P2Y12 receptors to chronic inflammatory pain in mice. Methods Complete Freund's adjuvant (CFA)‐induced chronic inflammatory pain was induced in wild‐type and P2ry12 gene‐deficient (P2ry12−/−) mice, and the potent, direct‐acting and reversible P2Y12 receptor antagonists PSB‐0739 and cangrelor were used. Results CFA‐induced mechanical hyperalgesia was significantly decreased in P2ry12−/− mice for up to 14 days, and increased neutrophil myeloperoxidase activity and tumor necrosis factor (TNF)‐α and CXCL1 (KC) levels in the hind paws were also attenuated in the acute inflammation phase. At day 14, increased interleukin (IL)‐1β, IL‐6, TNF‐α and KC levels were attenuated in P2ry12−/− mice. PSB‐0739 and cangrelor reversed hyperalgesia in wild‐type mice but had no effect in P2ry12−/− mice, and PSB‐0739 was also effective when applied locally. The effects of both local and systemic PSB‐0739 were prevented by A‐803467, a selective NaV1.8 channel antagonist, suggesting the involvement of NaV1.8 channels in the antihyperalgesic effect. Platelet depletion by anti‐mouse CD41 antibody decreased hyperalgesia and attenuated the proinflammatory cytokine response in wild‐type but not in P2ry12–/– mice on day 14. Conclusions In conclusion, P2Y12 receptors regulate CFA‐induced hyperalgesia and the local inflammatory response, and platelet P2Y12 receptors contribute to these effects in the chronic inflammation phase.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.13684